Cancer BiologybioRxiv
PTENP1-AS contributes to BRAF inhibitor resistance and is associated with adverse clinical outcome in stage III melanoma
L. Vidarsdottir, A. Azimi, I. Sigvaldadottir…·P. Johnsson
This study shows that PTENP1-AS contributes to BRAF inhibitor resistance and is linked to poor clinical outcomes in stage III melanoma.
DOI 10.1038/s41598-021-89389-9